Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(3.32) per share which beat the analyst consensus estimate of $(3.61) by 8.03 percent. This is a 55.01 percent increase over losses of $(7.38) per share from the same period last year. The company reported quarterly sales of $137.25 million which beat the analyst consensus estimate of $113.76 million by 20.64 percent.